

Conference Programme

19th Annual ENETS Conference
*for the Diagnosis and Treatment of
Neuroendocrine Tumor Disease*

10–11 March 2022, Barcelona, Spain

19th Annual ENETS Conference 2022

Programme

10 - 11 March 2022 - Hybrid Event

Thursday, 10 March 2022

Welcome

Time: Thursday 08:30 - 08:40

Marianne Pavel, GER

Opening session: Are we ready for precision medicine in NEN in 2022?

Time: Thursday 08:40 - 09:00

James Yao, USA

Session 1: Molecular pathology and precision medicine

Time: Thursday 09:00 - 10:30

Chairs: Anne Couvelard, FRA / Enrique Grande, ESP

- | | |
|---------------|--|
| 09:00 - 09:05 | Introduction
Anne Couvelard, FRA |
| 09:05 - 09:20 | Theranostic markers in well differentiated NET
Thomas Walter, FRA |
| 09:20 - 09:35 | Theranostic markers in NEC
Halfdan Sorbye, NOR |
| 09:35 - 09:55 | Panel discussion |
| 09:55 - 10:02 | Abstract presentation: Molecular characterization of a multi-institutional pan-lung cohort using integrative genomic and transcriptomic analysis
Michele Simbolo, ITA |
| 10:02 - 10:07 | Discussion |
| 10:08 - 10:15 | Abstract presentation: Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: The Gustave Roussy experience
Alice Boilève, FRA |
| 10:15 - 10:20 | Discussion |
| 10:20 - 10:30 | Putting molecular profiling into perspective
Jaume Capdevila, ESP |

Coffee break

Time: Thursday 10:30 - 11:00

Session 2A: New developments in nuclear medicine

Time: Thursday 11:00 - 12:15

Chairs: Vikas Prasad, GER / Irene Virgolini, AUT

- 11:00 - 11:15 **Moving beyond RECIST-PFS for assessment of outcome after PRRT**
Martyn Caplin, GBR
- 11:15 - 11:20 **Discussion**
- 11:20 - 11:35 **Integration of functional imaging and molecular pathology for optimal treatment selection in NEN**
Grace Kong, AUS
- 11:35 - 11:40 **Discussion**
- 11:40 - 11:55 **Modulation of targets for increasing the efficacy of PRRT**
Wolfgang Weber, GER
- 11:55 - 12:00 **Discussion**
- 12:00 - 12:10 **Abstract presentation: Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy**
Esben Andreas Carlsen, DEN
- 12:10 - 12:15 **Discussion**

Session 2B: Best abstracts - Clinical Science

Time: Thursday 11:00 - 12:15

Chairs: Wouter W. De Herder, NED / Simron Singh, CAN

- 11:00 - 11:07 **Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with PRRT**
Ramin Alipour, AUS
- 11:07 - 11:12 **Discussion**
- 11:12 - 11:19 **Risk of myelodysplastic syndrome/acute leukemia with sequential capecitabine/temozolomide and 177Lu-dotatate**
Taymeh Al-Toubah, USA
- 11:19 - 11:24 **Discussion**
- 11:24 - 11:31 **Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study**
Eric Baudin, FRA
- 11:31 - 11:36 **Discussion**
- 11:36 - 11:43 **Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study**
Jaume Capdevila, ESP
- 11:43 - 11:48 **Discussion**
- 11:48 - 11:55 **Nodal recurrence after curative surgery for non-functioning pancreatic neuroendocrine tumors: A retrospective cohort study**
Valentina Andreasi, POR
- 11:55 - 12:00 **Discussion**
- 12:00 - 12:07 **Minimally invasive laparoscopic and robotic versus open hepatic resection for NEN liver metastasis: Case matched study with propensity score matching**
Andreas Pascher, GER
- 12:07 - 12:15 **Discussion**

Lunch break

Time: Thursday 12:30 - 14:00

Satellite symposium – Industry-sponsored

Time: Thursday 12:30 - 14:00

Session 3A: Defining success and individualising therapy in NEN

Time: Thursday 14:00 - 15:15

Chairs: Dermot O'Toole, IRL / John Ramage, GBR

- 14:00 - 14:10 **What is the most appropriate outcome for quality-of-life measurements in trials and daily practice?**
Espen Thiis-Evensen, NOR
- 14:10 - 14:20 **Individualised treatment strategies**
Simron Singh, CAN
- 14:20 - 14:30 **Long term sequelae versus toxicity**
Eric Baudin, FRA
- 14:30 - 14:40 **Patient engagement in treatment decisions**
Catherine Bouvier, GBR
- 14:40 - 14:50 **Patient and caregiver NET lives / story**
Michael Rosenberg, ISR
- 14:50 - 15:15 **Discussion**

Session 3B: Best abstracts – Preclinical science

Time: Thursday 14:00 - 15:15

Chairs: Kjell Öberg, SWE / Aurel Perren, SUI

- 14:00 - 14:07 **Metabolomic profile of extra-pancreatic NET: A novel prognostic tool?**
Anna La Salvia, ESP
- 14:07 - 14:12 **Discussion**
- 14:12 - 14:19 **Comparative biocomputational analysis of the splicing landscape across lung neuroendocrine neoplasms unveils a new actionable molecular layer**
Ricardo Blázquez-Encinas, ESP
- 14:19 - 14:24 **Discussion**
- 14:24 - 14:31 **Cancer associated fibroblasts induce proliferation and therapeutic resistance in neuroendocrine tumors through STAT3 activation**
Tania Amin, GER
- 14:31 - 14:36 **Discussion**
- 14:36 - 14:43 **Longitudinal copy number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis and follow-up**
Laura Mariën, BEL
- 14:43 - 14:48 **Discussion**
- 14:48 - 14:55 **Comparison of drug sensitivity profiles of various NEN spheroids**
Po Hien Ear, USA
- 14:55 - 15:00 **Discussion**
- 15:00 - 15:07 **Patient-derived tumoroids phenocopy original gastro-entero-pancreatic neuroendocrine neoplasms and facilitate in vitro drug screening**
Simon April-Monn, SUI
- 15:07 - 15:15 **Discussion**

Coffee break

Time: Thursday 15:15 - 15:40

Session 4A: Joint session: European Society of Surgical Oncology (ESSO) / ENETS

Time: Thursday 15:40 - 17:05

Chairs: Detlef Klaus Bartsch, GER / Rocio Garcia-Carbonero, ESP / Stefan Stättner, AUT

PART 1 (15:40 - 16:20)

15:40 - 15:55 **A message from the ESSO president: Surgical oncology and NEN disease – Does one size fit all?**
Domenico D'Ugo, ITA

15:55 - 16:00 **Discussion**

16:00 - 16:15 **Trust the surgeon – Individual approaches and outcomes of pancreatic surgery**
Els Nieveen van Dijkum, NED

16:15 - 16:20 **Discussion**

PART 2: Surgery with curative intent to liver dominant disease – What is the number one choice? (16:20 - 17:05)

16:20 - 16:30 **The surgeon: Resection is king / Direct visibility / Regenerative potential and safe techniques**
Michel Rivoire, FRA

16:30 - 16:40 **The interventional radiologist: (Stereotactic) ablation does better than any surgical approach**
Reto Bale, AUT

16:40 - 16:50 **The transplant surgeon: Extended donor criteria will push transplantation to treatment of choice**
Cristina Dopazo, ESP

16:50 - 17:05 **Discussion**

Session 4B: Best abstracts – Clinical science

Time: Thursday 15:40 - 17:05

Chairs: Nicholas Simon Reed, GBR / Christos Toumpanakis, GBR

15:40 - 15:47 **Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)**
Siren Morken, NOR

15:47 - 15:52 **Discussion**

15:52 - 15:59 **Treatment response and survival according to molecular alterations in 229 patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN)**
Hege Elvebakken, NOR

15:59 - 16:04 **Discussion**

16:04 - 16:11 **Belzutifan, an oral hypoxia-inducible factor 2 α inhibitor, for Von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors**
Tobias Else, USA

16:11 - 16:16 **Discussion**

16:16 - 16:23 **Safety of Lanreotide Autogel 120mg plus Metformin in patients with advanced, well-differentiated gastrointestinal or lung NETs - A pilot, open-label, prospective study: The MetNET-2 Trial (NCT02823691)**
Sara Pusceddu, ITA

16:23 - 16:28 **Discussion**

16:28 - 16:35 **A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy**
Claudia von Arx, ITA

16:35 - 16:40 **Discussion**

16:40 - 16:47 **Incidence, prevalence and survival of neuroendocrine neoplasia 1995–2018**
Benjamin Easton White, GBR

16:47 - 16:52 **Discussion**

16:52 - 16:59 **Characterisation, prognosis, and treatment of patients with locally advanced or metastatic thymic carcinoid tumor: A retrospective study of the French GTE-ENDOCAN RENATEN and RYTHMIC networks**
Sarah Fodil-Cherif, FRA

16:59 - 17:05 **Discussion**

Poster session – Clinical science

Time: Thursday 17:05 - 17:35

Chairs: Nicholas Simon Reed, GBR / Christos Toumpanakis, GBR

- 17:05 - 17:11 **Ascl1 and OTP identify four prognostic groups among atypical carcinoids**
Giovanni Centonze, ITA
- 17:11 - 17:17 **Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy**
Timothy Price, AUS
- 17:17 - 17:23 **Opposite treatment approach in two institutes identifies primary tumor resection to be associated with improved disease specific mortality in patients with stage IV small intestinal neuroendocrine tumors (SI-NET) vs watch-and-wait strategy**
Sonja Levy, NED
- 17:23 - 17:29 **Sex differences in survival of neuroendocrine neoplasia in England 1995 - 2018**
Benjamin Easton White, GBR
- 17:29 - 17:35 **PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy**
Dermot O'Toole, IRL

Poster session – Basic science

Time: Thursday 17:05 - 17:35

Chairs: Aurel Perren, SUI / Anguraj Sadanandam, GBR

- 17:05 - 17:11 **Exploring the interplay between chromatin-remodeling genes and the regulation of alternative splicing and RNA biology in lung neuroendocrine neoplasms**
Antonio Agraz-Doblas, ESP
- 17:11 - 17:17 **Molecular characterization of the splicing machinery in pheochromocytomas and paragangliomas unveils a marked dysregulation with instructive potential**
Maria Trinidad Moreno-Montilla, ESP
- 17:17 - 17:23 **The chromosome 18 loss of heterozygosity axis of small intestinal neuroendocrine tumors**
Scott Waterfield, GBR
- 17:23 - 17:29 **Development and verification of a new monoclonal OTP specific antibody for pulmonary carcinoid diagnostics**
Ernst-Jan Speel, NED
- 17:29 - 17:35 **The first circulating tumor cell-derived explant (CDX) model of a Merkel cell carcinoma**
Melissa Frizziero, GBR

Coffee break

Time: Thursday 17:35 - 18:15

ENETS General Assembly (Members only)

Time: Thursday 18:15 - 19:30

Friday, 11 March 2022

Satellite symposium – Industry-sponsored

Time: Friday 07:30 - 08:30

Session 5: Systemic treatment of advanced NETs

– Have we made any progress?

Time: Friday 08:30 - 10:25

Chairs: Nicola Fazio, ITA / Marianne Pavel, GER

- 08:30 - 08:50 **What's changing our practice?**
Emily Bergsland, USA
- 08:50 - 08:55 **Discussion**
- 08:55 - 09:05 **Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin-5FU upon progression or the reverse sequence in advanced progressive panNETs: The SEQTOR study (GETNE 1206)**
Ramon Salazar, ESP
- 09:05 - 09:10 **Discussion**
- Debate on the optimal sequencing of systemic therapy in advanced Pancreatic NETs – What's the preferred option upon progression after one year of SSA therapy? (09:10 - 10:25)**
- 09:10 - 09:20 **Clinical case presentation**
Nicola Fazio, ITA
- 09:20 - 09:25 **Discussion**
- 09:25 - 09:33 **Defending everolimus**
Ramon Salazar, ESP
- 09:33 - 09:41 **Defending PRRT**
Tessa Brabander, NED
- 09:41 - 09:49 **Defending angiogenesis inhibitors**
Angela Lamarca, GBR
- 09:49 - 09:57 **Defending chemotherapy**
Michel Ducreux, FRA
- 09:57 - 10:05 **Defending high dose SSA**
Anja Rinke, GER
- 10:05 - 10:25 **Panel discussion**

Nurse symposium

Time: Friday 08:45 - 10:25

Chairs: Wanda Geilvoet, NED

- 08:45 - 08:50 **Welcome**
Wanda Geilvoet, NED
- Latest update in care for NET patients (08:50 - 09:55)**
Chairs: Wanda Geilvoet, NED & Lise Munk Plum, DEN
- 08:50 - 09:05 **'Assessing the landscape' - Patient experience**
Wendy Martin, GBR
- 09:05 - 09:20 **'Towing the line' - Dietitian guidelines**
Mette Borre, DEN
- 09:20 - 09:35 **'Mind the Gap!' - Immunotherapy trials**
Jenny Falkerby, SWE
- 09:35 - 09:45 **Global NET patient info pack**
Teodora Kolarova, BUL
- 09:45 - 09:55 **Discussion**
- Abstract session (09:55 - 10:20)**
Chairs: Wanda Geilvoet, NED & Wendy Martin, GBR
- 09:55 - 10:05 **Abstract presentation: Addressing professional development needs in neuroendocrine cancer nursing**
Nicola Jervis, GBR
- 10:05 - 10:15 **Abstract presentation: The role of the NET clinical nurse specialist in managing carcinoid heart disease patients: Optimising patient care**
Stacey Smith, GBR
- 10:15 - 10:20 **Discussion**
- 10:20 - 10:25 **Closing comments**
Wanda Geilvoet, NED

Coffee break

Time: Friday 10:25 - 10:55

Session 6: New developments in the management of high-grade NEC

Time: Friday 10:55 - 12:10

Chairs: Anna Koumariou, GRE / Juan Valle, GBR

- 10:55 - 11:10 **Impact of primary tumor site on treatment choices**
Nitya Raj, USA
- 11:10 - 11:15 **Discussion**
- 11:15 - 11:30 **Do recent results from clinical trials change the clinical management?**
Rocio Garcia-Carbonero, ESP
- 11:30 - 11:35 **Discussion**
- 11:35 - 11:50 **Current clinical trial landscape in NEC and future perspectives**
Rachel Riechelmann, BRA
- 11:50 - 11:55 **Discussion**
- 11:55 - 12:05 **NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 NENs of gastroenteropancreatic or unknown origin: Efficacy by differentiation, KI67 index and primary tumor site**
María del Carmen Riesco-Martinez, ESP
- 12:05 - 12:10 **Discussion**

Lunch break

Time: Friday 12:30 - 14:00

ENETS / INCA symposium - Advocacy approach to the diagnostic dilemma in NENs

Time: Friday 10:55 - 12:15

Chairs: Catherine Bouvier, GBR / Marianne Pavel, GER

- 10:55 - 10:58 **Welcome and introductions from ENETS/INCA**
Catherine Bouvier, GBR / Marianne Pavel, GER
- 10:58 - 11:03 **Detecting NENs: The patient story of a general practitioner (GP)**
David B., GBR
- 11:03 - 11:28 **Multidisciplinary team panel discussion**
Martyn Caplin, GBR / Sugandha Dureja, IND / Stefan Stättner, AUT / Eva Tiensuu Janson, SWE / Marie-Louise van Velthuisen, NED
- 11:28 - 11:35 **'Think NENs' Educational Program for GPs**
Mark McDonnell, IRL
- Advocacy and medical education best practice examples (11:35 - 11:50)**
- 11:35 - 11:40 **Overview of global best practice examples in advocacy**
Simone Leyden, AUS
- 11:40 - 11:45 **ENETS Educational Programme**
Eric Baudin, FRA
- 11:45 - 11:50 **The search for new biomarkers**
Enrique Grande, ESP
- 11:50 - 11:55 **Raising awareness on NENs on a global scale**
Teodora Kolarova, BUL
- 11:55 - 12:10 **Q&A Discussion**
- 12:10 - 12:15 **Wrap-up and closing comments**
Mark McDonnell, IRL / Marianne Pavel, GER

Satellite symposium - Industry-sponsored

Time: Friday 12:30 - 14:00

Session 7: Pheochromocytoma, paraganglioma and medullary thyroid carcinoma

Time: Friday 14:00 - 15:00

Chairs: Beata Kos-Kudła, POL / Anders Sundin, SWE

- 14:00 - 14:15 **Biomarkers and functional imaging of pheochromocytoma / paraganglioma and medullary thyroid cancer – Which modality should be used?**
Antongiulio Faggiano, ITA
- 14:15 - 14:20 **Discussion**
- 14:20 - 14:35 **Personalized treatment in advanced medullary thyroid carcinoma**
Daria Handkiewicz-Junak, POL
- 14:35 - 14:40 **Discussion**
- 14:40 - 14:55 **Personalized treatment in advanced paragangliomas and pheochromocytomas**
Simona Glasberg, ISR
- 14:55 - 15:00 **Discussion**

Life Achievement Award

Time: Friday 15:00 - 15:20

- 15:00 - 15:10 **Laudatio**
Marianne Pavel, GER
- 15:10 - 15:20 **Recipient and keynote address**
Günter Klöppel, GER

Awards ceremony

Time: Friday 15:20 - 15:35

Session 8: What's new in 2021/2022?

Time: Friday 15:35 - 16:20

- 15:35 - 16:05 **Best abstract resumé - Clinical science**
Robert T. Jensen, USA
- 16:05 - 16:20 **Review of basic science**
Eva Tiensuu Janson, SWE

Welcome the new ENETS Chair & Closing comments

Time: Friday 16:20 - 16:30

Marianne Pavel, GER / Eva Tiensuu Janson, SWE